Opportunities and Challenges of RNA Interference Therapeutics in Oncology / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 482-486, 2022.
Article
em Zh
| WPRIM
| ID: wpr-939735
Biblioteca responsável:
WPRO
ABSTRACT
As the discovery of RNA interference (RNAi) and the gradual conquering of a series of technical issues, a few of RNAi therapeutics have been approved in the non-tumor field abroad. With the advantages of high specificity, long duration of efficacy, and high success rate of development, RNAi therapeutics have become the emerging field globally. There are no RNAi therapeutics approved in oncology so far, and people are hoping a breakthrough in the field. In the present article, the characteristics and potential anti-tumor mechanism of RNAi therapeutics, difficulties in delivery system and progress in oncology are described, and the potential reasons why their success in non-tumor field is difficult to be simply replicated in tumor field are analyzed, providing reference for research and clinical transformation of RNAi therapeutics in oncology.
.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
RNA Interferente Pequeno
/
Interferência de RNA
/
Neoplasias Pulmonares
Limite:
Humans
Idioma:
Zh
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2022
Tipo de documento:
Article